02:23 AM EDT, 08/10/2026 (MT Newswires) -- Nicox's (ALCOX.PA) exclusive licensee in China, Ocumension Therapeutics, lodged a new drug application for eye drop NCX 470 as a treatment to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The application to the Center for Drug Evaluation of China's National Medical Products Administration includes data from the phase 3 Mont Blanc and Denali trials, with the latter including Chinese clinical sites, the Paris-listed ophthalmology company said Monday.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.